Request for Nominations of Specific Drug/Biologic Product(s) That Could Be Brought Before the Food and Drug Administration's Pediatric Subcommittee of the Oncologic Drugs Advisory Committee
Notice; Request For Product Nominations.
The Food and Drug Administration's (FDA) Office of Hematology and Oncology Products invites the public to suggest one or more specific drug or biologic products that could be brought before the December 4, 2012, Pediatric Subcommittee of the Oncologic Drugs Advisory Committee (ODAC). The number of drugs studied for use in pediatric patients is growing, and we see a reduction in off-label use. However, we would like to improve current and future pediatric product development by focusing on products whose development would benefit the most from the attention of an advisory committee. The company developing a product that is brought before the committee will be given the unique opportunity to present proposed pediatric studies in the United States, share their plans for global pediatric development, and hear discussions by the Pediatric Subcommittee on possible directions for their current or future pediatric oncology product development.
Table of Contents Back to Top
DATES: Back to Top
Nominations must be received by September 4, 2012, to receive consideration for inclusion. Nominations received after this date will receive consideration for future meetings of the Pediatric Subcommittee of the ODAC.
ADDRESSES: Back to Top
Email nominations to Christine.Lincoln@fda.hhs.gov, and please include the subject line “Suggested Product for 2012 Pediatric Oncology Subcommittee of ODAC.”
FOR FURTHER INFORMATION CONTACT: Back to Top
Christine Lincoln, RN, MS, MBA, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 2206, Silver Spring, MD 20993, 301-796-4117, Christine.Lincoln@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Back to Top
The Food and Drug Administration (FDA) Advisory Committees are an important, transparent interface that allows the Agency to include the public in its decision-making processes. Significant public health and safety issues are brought before these committees for deliberation, and the meetings bring together both experts with state-of-the-art knowledge and members of the public with relevant personal experiences. This broad participation gives FDA a unique perspective as it seeks to assure the safety, efficacy, and security of FDA-regulated products.
Additional information about the prior November 2, 2011, Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee may be found on FDA's Web site at: http://www.fda.gov/AdvisoryCommittees/Calendar/ucm274396.htm.
Dated: August 2, 2012.
Assistant Commissioner for Policy.
[FR Doc. 2012-19330 Filed 8-7-12; 8:45 am]
BILLING CODE 4160-01-P